Mereo BioPharma Group plc (MREO)
NASDAQ: MREO · Real-Time Price · USD
0.4239
-0.0081 (-1.87%)
At close: Feb 20, 2026, 4:00 PM EST
0.4209
-0.0030 (-0.71%)
After-hours: Feb 20, 2026, 7:35 PM EST
Mereo BioPharma Group Revenue
Mereo BioPharma Group had revenue of $500.00K in the twelve months ending September 30, 2025, down -50.00% year-over-year.
Revenue (ttm)
$500.00K
Revenue Growth
-50.00%
P/S Ratio
134.91
Revenue / Employee
$13,889
Employees
36
Market Cap
67.46M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | 10.00M | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 49.37M | - | - |
| Dec 31, 2020 | - | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMREO News
- 3 days ago - Shareholders who lost money in shares of Mereo BioPharma Group PLC (NASDAQ: MREO) should contact Wolf Haldenstein immediately - PRNewsWire
- 3 days ago - Stockholders Who Lost Money Investing in Mereo BioPharma Group plc Should Contact Robbins LLP for Information About Recovering Their Losses from MREO - GlobeNewsWire
- 12 days ago - UPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Mereo BioPharma - Newsfile Corp
- 5 weeks ago - Mereo BioPharma Group plc (MREO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 7 weeks ago - These biotech stocks are getting hammered by shocking brittle-bone treatment study results - Market Watch
- 7 weeks ago - Mereo BioPharma Announces Phase 3 ORBIT and COSMIC Results for Setrusumab (UX143) in Osteogenesis Imperfecta - GlobeNewsWire
- 6 months ago - āshibio Expands Clinical Pipeline with Vantictumab, a First-In-Class Antibody for Autosomal Dominant Osteopetrosis Type 2 - Business Wire
- 6 months ago - Mereo BioPharma Reports Second Quarter 2025 Financial Results and Provides Corporate Highlights - GlobeNewsWire